Advertisement

Topics

FDA approves expanded use of AstraZeneca ovarian cancer drug

09:22 EDT 18 Aug 2017 | Topix

The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. The agency also approved a new two-tablet regimen for the drug, regardless of whether patients test positive for BRCA genetic mutations associated with high risk for the cancer.

Original Article: FDA approves expanded use of AstraZeneca ovarian cancer drug

NEXT ARTICLE

More From BioPortfolio on "FDA approves expanded use of AstraZeneca ovarian cancer drug"

Advertisement
Quick Search
Advertisement
Advertisement